Abbott tries to throw up roadblock to Humira biosim

While Pfizer ($PFE) was reporting a 71% drop in U.S. Lipitor sales and plotting its next spinoff move, Abbott Laboratories ($ABT) was working to shore up its own breakup plans by protecting its pharma unit's lead drug. The Chicago-based company petitioned the FDA to stop biosimilar versions of Humira, its lead drug, on trade-secret grounds. Report

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.